Open an Account
search icon
4
NOTIFICATIONS
Best Algo trading app in India
Bigul

Thyrocare Technologies Ltd - 539871 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

 Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to intimate that a conference call for the Indian and overseas analysts is arranged by our management to discuss the Company's financial results for Quarter / Six Months ended September 30, 2020, on Tuesday, November 03, 2020 at 12.00 Noon local time. Dr. A. Velumani, Chairman & Managing Director, Mr. Arindam Haldar, Chief Executive Officer, Mr. A. Sundararaju, CFO & Executive Director and Mr. Sachin Salvi, Vice-President- Finance, will represent the Company. Dial-in details are given in the copy of enclosed Invite of M/s. Nomura Financial Advisory & Securities (India) Pvt. Ltd., who is organizing the con-call.
02-11-2020
Bigul

Thyrocare Technologies Ltd - 539871 - Corporate Action- Record Date For The Purpose Of Dividend Is November 13, 2020

 Please refer to our letter dated 28-10-2020 communicating the outcome of the Board Meeting held yesterday, wherein we had intimated to you that the Board of Directors of the Company have declared an Interim Dividend of Rs. 10/- (Rupees Ten only) Per Share for the Financial Year 2020-21. Please note that Friday, 13th November 2020, has been fixed as the record date for the purpose of determining the eligibility of shareholders for the interim dividend as above.
29-10-2020
Bigul

Thyrocare Technologies Ltd - 539871 - Board declares Interim Dividend

 Thyrocare Technologies Ltd has informed BSE that the Board of Directors of the Company at its meeting held on October 28, 2020, inter alia, have approved payment of interim dividend for the financial year 2020-21, at the rate of Rs. 10/- (Rupees Ten only) per share (100% of the face value of Rs. 10/ each).
29-10-2020
Bigul

Thyrocare Technologies Ltd - 539871 - Announcement under Regulation 30 (LODR)-Investor Presentation

 We are forwarding a copy of Presentation on Quarterly Results of our company for the quarter / half year ended 30-09-2020. Please note that this is only uploaded in our website, and has not been distributed or advertised in newspapers or otherwise publicised.
28-10-2020
Bigul

Thyrocare Technologies Ltd - 539871 - Results- Financial Results For The Period Ended 30-09-2020

 This is inform that the BOD, at their meeting held today, approved unaudited FR (Stand-alone and Consolidated) for the Quarter / Half year ended 30-09-2020 and also approved payment of interim dividend for the FY 2020-21, at the rate of Rs. 10/- The Stand-alone and Consolidated unaudited FR for the quarter / half year ended 30-09-2020, along with the Limited Review Reports, are attached pursuant to Regulation 33 (3) (a) to (c) of SEBI (LODR) Regulations, 2015. We declare that Statutory auditors have issued unmodified opinion on both the Stand-alone and Consolidated Financial Results. The BOD took on record the recent changes in the KMP: 1. Dr. A. Velumani, Chairman, who was reappointed at the 20th AGM held on 29-09-2020 would be the MD. 2. Mr. A. Sundararaju, who was reappointed at the 20th AGM held on 29-09-2020 would be the Executive Director & CFO. 3. Mr. Arindam Haldar would be the CEO. Meeting commenced at 17.00 hours and ended at 21.10 hours today, the 28-10-2020
28-10-2020
Bigul

Thyrocare Technologies Ltd - 539871 - Outcome Of Board Meeting Held On 28-10-2020

 Outcome of Board Meeting held on 28-10-2020
28-10-2020
Bigul

Thyrocare rallies 10%, hits record high on expectation of strong Q2 results

 Earlier this month, the company reported nearly 37 per cent year-on-year and over 100 per cent sequential growth in aggregate revenue for Q2FY21
26-10-2020
Bigul

Thyrocare Technologies Ltd - 539871 - Board Meeting Intimation for Intimation Of Board Meeting To Be Held On 28-10-2020 To Consider And Approve Quarterly Financial Results And To Consider And Decide On Payment Of Interim Dividend, If Any, For The FY 2020-21

 Thyrocare Technologies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/10/2020 ,inter alia, to consider and approve Pursuant to Regulation 29 (1) (a) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, we wish to intimate that a meeting of our Board of Directors of the Company will be held on Wednesday, October 28, 2020, to inter alia, consider and approve Unaudited Stand-alone and Consolidated Financial Results of the Company for the quarter / half year ended September 30, 2020, and to consider and decide on payment of Interim Dividend, if any, for the financial year 2020-21. Intimation of the above meeting of the Board of Directors is also being published in newspapers, as required under Regulation 47 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015.
20-10-2020
Bigul

Thyrocare Technologies Ltd - 539871 - Compliances- Compliance Certificate Under Regulation 40 (9) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015, For The Half Year Ended September 30, 2020

 We are filing herewith the Compliance Certificate dated 16-10-2020 issued by Mr. V. Suresh, Practising Company Secretary, pursuant to the Regulation 40 (9) of Securities & Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, for the Half-year ended September 30, 2020. Please take the same on record.
17-10-2020
Bigul

Thyrocare Technologies Ltd - 539871 - Shareholding for the Period Ended September 30, 2020

 Thyrocare Technologies Ltd has submitted to BSE the Shareholding Pattern for the Period Ended September 30, 2020. For more details, kindly Click here
14-10-2020
Next Page
Close

Let's Open Free Demat Account